title: Role of IL-1 alpha in central nervous system immunomodulation of glucoregulation.
abstract: Hyperglycemia is a hallmark of the stress response, and has been largely attributed to elevated plasma levels of catabolic hormones. Recently, various cytokines have been shown to be endogenously produced within the brain and may represent an important component of the central regulation of this metabolic response. Therefore, the aim of the present study was to determine whether the intracerebroventricular (i.c.v.) injection of one such peptide, interleukin (IL)-1, can produce hormonal and metabolic alterations comparable to those observed under stress conditions. An i.c.v. cannula and vascular catheters were placed in rats prior to the experiment. Whole body glucose flux was assessed in overnight fasted conscious unrestrained rats using [3-3H]glucose. A mild hyperglycemia was elicited 20 min after the i.c.v. injection of IL-1 alpha (human recombinant, 100 ng) that was not detected in control rats. Glucose levels gradually increased and were 26% higher than control values during the last hour of the 3 h experimental period. The hyperglycemia resulted from a 44% increase in the rate of hepatic glucose output (HGO), which preceded a proportional rise in peripheral glucose utilization. No increase in metabolic clearance rate was observed, suggesting that the increased glucose uptake was the result of mass action. The increased glucose flux was associated with a transient hyperinsulinemia (+95%), and sustained elevations in the arterial concentrations of glucagon (56%) and corticosterone (175%). In contrast, glucose flux was not altered by intravenous administration of the same dose of IL-1 alpha, or i.c.v. injection of IL-1 beta, or heat-inactivated IL-1 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, State University of New York at Stony Brook 11794-8191.
authors.forename: C H
authors.initials: CH
authors.lastname: Lang
authors.forename: P E
authors.initials: PE
authors.lastname: Molina
authors.forename: K A
authors.initials: KA
authors.lastname: Yousef
authors.forename: P G
authors.initials: PG
authors.lastname: Tepper
authors.forename: N N
authors.initials: NN
authors.lastname: Abumrad
mesh_terms: D000276:Adjuvants, Immunologic / Q000502:physiology*; D000818:Animals; D002490:Central Nervous System / Q000502:physiology*; D015232:Dinoprostone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000378:metabolism*; D006728:Hormones / Q000097:blood; D007276:Injections, Intraventricular; D007375:Interleukin-1 / Q000502:physiology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins
chemical_list: D000276:Adjuvants, Immunologic; D006728:Hormones; D007375:Interleukin-1; D011994:Recombinant Proteins; D005947:Glucose; D015232:Dinoprostone